Worg key facts
as of Oct 2026- Developer of a clinical-stage biopharmaceutical company intended to find treatments for allergies and diseases with high unmet medical needs and considerable commercial potential.
- Worg is valued at approximately $247.8M as of Oct 2026 (last reported valuation).
- It has raised $285.3M; the latest was Secondary Transaction - Private in Nov 2025.
- Notable investors include Puhua Capital, Hefei Hi-Tech VC, Lapam Capital, Detong Capital, Wuxi Jinkong Qiyuan Investment — 18 tracked in total.
- Status: Privately Held (backing).
Worg's last reported valuation, Aug 2022. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch Worg: the Monday email on marks, rounds and moves
Worg funding rounds
No funding rounds for Worg are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Worg valuation
Worg's last reported valuation was $248 million in Aug 2022. No priced round, secondary trade or fund mark has surfaced since.
Worg investors
18 investors are on record for Worg, including Puhua Capital, Hefei Hi-Tech VC, Lapam Capital and Detong Capital.
About Worg
Developer of a clinical-stage biopharmaceutical company intended to find treatments for allergies and diseases with high unmet medical needs and considerable commercial potential. The company offers building a pipeline for immunotherapy of allergies, autoimmune diseases, and other disorders through internal development and external partnering, enabling the acceleration of new treatment development.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Employees
- 40
- Website
- worgpharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.